FY2025 EPS Estimates for RARE Reduced by Cantor Fitzgerald

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Equities researchers at Cantor Fitzgerald lowered their FY2025 EPS estimates for Ultragenyx Pharmaceutical in a research note issued on Monday, July 14th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biopharmaceutical company will post earnings of ($5.15) per share for the year, down from their prior estimate of ($5.08). The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($5.18) per share. Cantor Fitzgerald also issued estimates for Ultragenyx Pharmaceutical's FY2026 earnings at ($3.00) EPS.

Other research analysts have also recently issued reports about the stock. Wedbush decreased their price objective on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a report on Monday, July 14th. Guggenheim reaffirmed a "buy" rating and set a $64.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 20th. William Blair began coverage on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, May 28th. They set an "outperform" rating and a $65.00 target price for the company. Wells Fargo & Company dropped their price target on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating on the stock in a research note on Thursday, July 10th. Finally, JPMorgan Chase & Co. upped their price objective on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical presently has a consensus rating of "Moderate Buy" and a consensus target price of $83.64.

Ultragenyx Pharmaceutical Stock Performance

Shares of Ultragenyx Pharmaceutical stock traded down $1.10 during midday trading on Wednesday, reaching $26.31. 3,904,088 shares of the company's stock traded hands, compared to its average volume of 976,201. Ultragenyx Pharmaceutical has a 12 month low of $26.00 and a 12 month high of $60.37. The company has a market cap of $2.49 billion, a PE ratio of -4.47 and a beta of 0.26. The stock has a 50 day moving average of $35.65 and a 200-day moving average of $38.25.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.03). The firm had revenue of $139.29 million for the quarter, compared to analyst estimates of $145.98 million. Ultragenyx Pharmaceutical had a negative return on equity of 186.49% and a negative net margin of 93.04%. Ultragenyx Pharmaceutical's revenue for the quarter was up 28.0% compared to the same quarter last year. During the same period in the previous year, the company earned ($2.03) earnings per share.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Several hedge funds have recently modified their holdings of RARE. Parallel Advisors LLC boosted its position in shares of Ultragenyx Pharmaceutical by 1,061.9% in the 2nd quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 669 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Ultragenyx Pharmaceutical by 76.2% in the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 323 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new position in shares of Ultragenyx Pharmaceutical in the 4th quarter valued at approximately $35,000. ANTIPODES PARTNERS Ltd purchased a new stake in Ultragenyx Pharmaceutical during the 1st quarter worth approximately $57,000. Finally, Headlands Technologies LLC acquired a new stake in Ultragenyx Pharmaceutical during the 1st quarter worth about $59,000. Hedge funds and other institutional investors own 97.67% of the company's stock.

Insider Activity

In other news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $37.39, for a total transaction of $89,922.95. Following the completion of the sale, the director owned 15,344 shares of the company's stock, valued at approximately $573,712.16. The trade was a 13.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last three months, insiders sold 3,167 shares of company stock worth $118,824. 5.50% of the stock is currently owned by company insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.